Some examples include inhibiting PRMT1/ATF5 in neuroblastomas, increasing the level of ATF5 inhibition-related miRNAs in gliomas, targeting the Fis-1/ATF5 axis in metabolic diseases, or targeting ATF5 in diabetes. This evidence concerns the gene PRMT1 and neuroblastoma.